Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Skin Neoplasms 1Sarcoma, Kaposi 1Lymphoproliferative Disorders 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

pembrolizumab 6Nivolumab 5cemiplimab 3Photochemotherapy 3Ipilimumab 3Vemurafenib 2Hsp90 inhibitor KU757 2tozuleristide 1toripalimab 1tislelizumab 1spartalizumab 1small molecule inhibitor THX-B 1poly ICLC 1montanide ISA 51 1liposomal doxorubicin 1durvalumab 1dostarlimab 1cobimetinib 1cc-486 1brodalumab 1avelumab 1atezolizumab 1Ultraviolet Rays 1Tumor Necrosis Factor-alpha 1Sunscreening Agents 1Sugars 1SUB1 protein, human 1Radiotherapy 1Propranolol 1Poly I-C 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Skin Neoplasms × 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone × Clear all
NCT00002153 2005-06-24

Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
25 enrolled
DermatologicLymphoidSarcoma

Acquired Immunodeficiency Syndrome, Lymphoproliferative Disorders, Sarcoma, Kaposi, Skin Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡